Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsEffects of L-dopa during auditory instrumental learning in humans.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Functional brain networks in movement disorders: recent advancesEffects of levodopa on regional cerebral metabolism and blood flowGlutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.Metabolic brain networks in translational neurology: concepts and applications.Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson's Disease patients assessed using pseudo-continuous arterial spin labeling.Parkinson's disease: increased motor network activity in the absence of movementCombined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson's disease.The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesial-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Vascular inter-regulation of inflammation: molecular and cellular targets for CNS therapy.Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia.Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis.Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery
P2860
Q21129423-DA2B6E1A-E88A-487F-B831-BCA45B917E8AQ30459431-C197DB29-87ED-41D0-BAD4-ACE8F93F810EQ30833645-74CF9770-C43C-4E9D-942C-71C06DB9E617Q34308197-06DE5D67-0417-4B28-8DCD-F10A1BEC6CCEQ35040119-C0CAB784-CA40-4755-AF36-AA5F2817DCEFQ35124773-63F0E86F-C2B6-4090-872B-49F5025E1F19Q36041821-9D9302F3-4033-41D6-9ECB-22801943D52AQ36198357-F681DDF8-B41F-4830-AAEB-547C83A91178Q36314846-1A503D76-86D9-489D-9C50-91548F9C9EF5Q36426177-D29FC4CE-73DE-464E-90E4-C0A31A99AC85Q36899657-BFCB2F56-56EF-45BA-9E23-ACE081F75160Q37267022-C22800C7-CD5F-4BD3-BCE1-92097AA63D17Q37270927-5075860C-21C1-442E-BCF6-CB291BAA71D4Q37277039-9B385B61-3F13-4510-B9DC-C2B9C870E185Q38951947-E0A5CAC0-AF43-4CF0-BA71-2347580B331BQ39031301-4D6AA94E-7E3B-41F4-856B-AD43EF3F8764Q39470500-5BF1E3BB-1460-411F-B051-E0CC6932A8FAQ45423232-F8F0EC34-2289-4397-A8D7-57D096A3524EQ47116959-D65A1C0E-E74C-479B-8CEE-2094B7F67F9FQ47357393-3C555227-475A-44B0-9D97-99CEE6BF92A0Q48475595-B1437E3F-2156-4C43-A1F6-BCAA7D05AF37Q50091410-5C246A2E-893C-4AD7-AA8B-1E79B7CAAFD6Q55546568-B9B90CC3-6C51-4F67-AC0E-8964E8BE800DQ57176938-1B07889B-D386-40B4-B048-6630A897E203
P2860
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@ast
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@en
type
label
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@ast
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@en
prefLabel
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@ast
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@en
P2093
P2860
P50
P1433
P1476
Impact of L-DOPA treatment on ...... model of Parkinson's disease.
@en
P2093
Chris E Adkins
M Angela Cenci
Paul R Lockman
P2860
P304
P356
10.1016/J.NEUROIMAGE.2012.02.066
P407
P577
2012-03-03T00:00:00Z